Princess Margaret Cancer Centre ( Site 0202)

Toronto, Ontario M5G 2M9

3 studies enrolling now · 5 studies all time

What they study most

Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors, Biliary Tract Cancers, Colorectal Cancer, Gastric Cancer, Glioblastoma, HIF-2α Mutated Cancers, Head and Neck Neoplasms, Malignant Neoplasm, Ovarian Cancer, Pancreatic Cancer, Pancreatic Neuroendocrine Tumor

Studies at this site

• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) — Recruiting now
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) — Recruiting now
• A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) — Recruiting now
• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) — Running, not enrolling
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) — Completed